December 2, 2021

Raven Tribune

Complete News World

Novavax: The new vaccine actually works well against corona

  • FromDominic John

    To the end

Novavox: The vaccine is not yet approved in Europe. Nevertheless, the EU is concluding agreements with manufacturers for more than 100 million cans.

The booster wave is blowing in Germany. Adequate vaccination must be found. Current numbers of corona virus echo24.de Show significant growth. For the first vaccinations. Now, with Novavax, a new type of vaccine may soon be approved in Europe. This improvement may lead to reconsideration, especially for those who are skeptical of the vaccine. But how good is Novavax? How well does it protect against corona?

One of the benefits of Novavax is savings. As a protein vaccine, it can be stored in the refrigerator at room temperature. Approves approval for US manufacturer in EU – European Pharmaceuticals Agency (EMA) decision loud Wirtschaftswoche Expected in a few weeks.

Novavox vaccine before approval: Agreement with the EU from August

According to an earlier announcement by EMA, the agreement with pharmaceutical company Novavax has been in effect since August, allowing EU member states to purchase up to 100 million doses of the vaccine. At the time, Commission Chairman Ursula van der Leyen said: “As the new corona virus strains spread in Europe and around the world, this new agreement with a company that has been successfully testing the vaccine on these strains is another protection to protect our people. It strengthens our vast vaccination portfolio for the benefit of people in Europe and our partners around the world.

Novovax: How well does the vaccine pot protect against corona?

The vaccine has not yet been approved. But like that Drug Newspaper Writes that the company has released the final study data for the “Phase III Prevention-19 study”. Accordingly, only 14 people who were vaccinated in the study were not moderately or severely affected by Govt-19 disease. The way to Europe now seems to be entirely a matter of form.

See also  Corona: Many times more common among people who have not been vaccinated

The first victories were already evident in mid-June. According to the then study, the effectiveness of the vaccine was 90.4 percent. This means that people who have been vaccinated twice have had 90 percent fewer cases of coronary heart disease than those in the control group.

The third phase of the study involved 30,000 adults in the United States and Mexico. When selecting exam subjects, step by step Drug Newspaper The focus was on those of different races and those at high risk for severe Govit-19 courses.

Background of the study for the novovax vaccine

As a result of the article “Two-thirds of participants received two vaccine doses at 21-day intervals, and one-third received placebo injections according to the same vaccination schedule. A total of 77 symptomatic corona infections occurred in 14 of those vaccinated and 63 in the placebo group; Most of them were induced by alpha variation (B.1.1.7). This equates to 90.4 percent efficiency.

Protection against moderate to severe disease progression was ultimately even 100 percent. However, with the new vaccine, the fear of side effects always comes back to many. As echo24.de Isolated participants were reported to have side effects in experiments with nuvoxovit.

Novavox has vaccine protection against corona variants

In another Phase III study of about 15,000 participants in the UK, the novovax vaccine was able to prove itself against the then-new variants of the corona virus alpha and beta. According to the New England Journal of Medicine, vaccinated “SARS-CoV-2 showed 89.7 percent protection against infection and high performance against B.1.1.7 variant “.

The novovax vaccine is approved in many countries

While you still have to wait for approval for Europe, the US company Novavax is already on the market in other countries and has been vaccinated. Indonesia was the first country in early November and the Philippines in mid-November. As unteranderem br.de writes, the manufacturer had already applied for approval for Great Britain by the end of October.

See also  Problems with BioNTech and Moderna Omikron? Does Valneva have a solution?

According to the report, the company has so far postponed the application for the US market. However, by the end of 2021, the FDA should be there too.

Title Image: © Frank Hormon / SVEN SIMON / dpa